When prescribing SSRIs for children and adolescents, the FDA black box warning requires informing families about increased risk of:
-
A
Tardive dyskinesia
-
B
Suicidal ideation and behavior in patients under 25
-
C
Serotonin syndrome in all pediatric patients
-
D
QTc prolongation